Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. by Lai, Wai et al.
 
 
University of Birmingham
Expression of DC-SIGN and DC-SIGNR on human
sinusoidal endothelium: a role for capturing
hepatitis C virus particles.
Lai, Wai; Sun, PJ; Zhang, J; Jennings, Adam; Lalor, Patricia; Hubscher, Stefan; McKeating,
Jane; Adams, David
Citation for published version (Harvard):
Lai, W, Sun, PJ, Zhang, J, Jennings, A, Lalor, P, Hubscher, S, McKeating, J & Adams, D 2006, 'Expression of
DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles.', The
American Journal of Pathology, vol. 169, no. 1, pp. 200-8.
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Immunopathology and Infectious Diseases
Expression of DC-SIGN and DC-SIGNR on Human
Sinusoidal Endothelium
A Role for Capturing Hepatitis C Virus Particles
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Stefan Hubscher,* Jane A. McKeating,† and
David H. Adams*
From the Liver Research Group* and the Hepatitis C Virus
Laboratory,† Medical Research Council Centre for Immune
Regulation, Institute of Biomedical Research, University of
Birmingham Medical School, Edgbaston, Birmingham,
United Kingdom
Hepatic sinusoidal endothelial cells are unique
among endothelial cells in their ability to internalize
and process a diverse range of antigens. DC-SIGNR, a
type 2 C-type lectin expressed on liver sinusoids, has
been shown to bind with high affinity to hepatitis C
virus (HCV) E2 glycoprotein. DC-SIGN is a closely re-
lated homologue reported to be expressed only on
dendritic cells and a subset of macrophages and has
similar binding affinity to HCV E2 glycoprotein. These
receptors function as adhesion and antigen presenta-
tion molecules. We report distinct patterns of DC-
SIGNR and DC-SIGN expression in human liver tissue
and show for the first time that both C-type lectins are
expressed on sinusoidal endothelial cells. We con-
firmed that these receptors are functional by demon-
strating their ability to bind HCV E2 glycoproteins.
Although these lectins on primary sinusoidal cells
support HCV E2 binding, they are unable to support
HCV entry. These data support a model where DC-
SIGN and DC-SIGNR on sinusoidal endothelium pro-
vide a mechanism for high affinity binding of cir-
culating HCV within the liver sinusoids allowing
subsequent transfer of the virus to underlying hepa-
tocytes , in a manner analogous to DC-SIGN presen-
tation of human immunodeficiency virus on den-
dritic cells. (Am J Pathol 2006, 169:200–208; DOI:
10.2353/ajpath.2006.051191)
Collectins comprise a family of calcium-dependent pat-
tern-recognition lectins that bind oligosaccharide struc-
tures on the surface of microorganisms to facilitate clear-
ance through aggregation, complement lysis, and
opsonization. Two members of this family, DC-SIGN
(CD209) and the related molecule DC-SIGNR (L-SIGN,
CD209L), have been extensively studied for their ability to
bind a variety of viral pathogens.1–10 Indeed, these mol-
ecules are often referred to as ‘viral attachment factors’
and can potentiate infectivity of some viruses.11 DC-SIGN
is reported to be expressed on a subset of macrophages
and dendritic cells,12–16 whereas DC-SIGNR is ex-
pressed on endothelial cells within the liver sinusoids and
lymph nodes.11,17 DC-SIGN promotes cellular uptake
and presentation of antigen and potentiates the interac-
tion of DC-SIGN-expressing cells with leukocytes via an
interaction with intercellular adhesion molecule-3.18 Re-
cent biochemical and structural studies suggest that DC-
SIGN and DC-SIGNR have different physiological func-
tions and distinct ligand-binding properties.19
Hepatitis C virus (HCV)3 is an enveloped positive-
stranded RNA virus and the sole member of the Hepaci-
virus genus, within the family Flaviviridae. Approximately
170 million individuals are infected worldwide, and the
majority are at risk of developing progressive liver dis-
ease. Cellular and humoral immune responses are gen-
erated during HCV infection, but in the majority of indi-
viduals, humoral immune responses are inefficient to
effect viral clearance, with 80% of new infections be-
coming chronic. The liver is thought to be the primary
reservoir supporting HCV replication, although studies on
HCV cell entry and tropism have been limited due to
Supported by the Medical Research Council (clinical training fellowship to
W.K.L.), the Biotechnology and Biological Sciences and Research Coun-
cil, and the National Institutes of Health (grant R01AI50798-01A1).
Accepted for publication April 4, 2006.
Address reprint requests to Drs. Wai Kwan Lai or David H. Adams, Liver
Research Laboratories, Institute of Biomedical Research, Birmingham
University, Edgbaston, B15 2TH, United Kingdom. E-mail: w.k.lai@
bham.ac.uk and d.h.adams@bham.ac.uk.
American Journal of Pathology, Vol. 169, No. 1, July 2006
Copyright © American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.051191
200
technical difficulties in propagating infectious HCV in cell
culture. However, the recent development of infectious
retroviral pseudotypes bearing HCV glycoproteins
(HCVpp)20–22 and the robust replication of HCV strain
JFH in cell culture (HCVcc)8,23–25 have enabled studies
on HCV cell entry. HCVpp and HCVcc show a restricted
tropism for human liver cell lines, and infection is depen-
dent on CD81 expression.20–22,24–26 We6 and oth-
ers2,4,5,27 demonstrated that HCVpp can interact with
DC-SIGN- and DC-SIGNR-expressing cells; however, the
physiological relevance of these virus-lectin interactions
for HCV infection of the liver remains unclear.
Hepatic sinusoidal endothelial cells (HSECs) are
unique among endothelial cells in their ability to internal-
ize and process a diverse range of antigens.28 In contrast
to most other endothelial cells, HSECs can process and
present antigen to naive CD4 T cells and cross prime
CD8 T cells. This latter response may lead to antigen-
specific tolerance rather than immunity, suggesting the
HSECs may contribute to the tolerogenic properties of the
liver.29,30 This is of particular relevance in the setting of
HCV infection if one considers its chronic nature and the
apparent ineffectiveness of the cellular immune re-
sponses. A single report of DC-SIGN expression in brain
microvascular endothelial cells31 supports a model
where DC-SIGN may be expressed by HSECs and con-
tribute to their unique antigen-presenting capabilities and
regulation of immune responses to pathogens entering
the liver.
Here, we report distinct patterns of DC-SIGNR and
DC-SIGN expression in human liver tissue and show that
both C-type lectins are expressed on HSECs. We confirm
that these receptors are functional by demonstrating their
ability to bind HCV E2 protein and show that stimulation of
isolated HSECs with interleukin-4 (IL-4) increases expres-
sion of both DC-SIGN and DC-SIGNR, promoting HCV E2
binding. However, isolated HSECs do not support
HCVpp or HCVcc infection, suggesting that expression of
these receptors is not sufficient to render these cells
permissive for HCV infection. Expression of DC-SIGN on
HSECs may allow internalization of antigens, including
HCV particles for subsequent processing and presenta-
tion to naı¨ve T cells. If these interactions result in ineffec-
tive T-cell activation or tolerance, they may contribute to
the failed immune response against HCV infection.
Materials and Methods
Tissue Studied
Ethics approval for the study was given by the South
Birmingham Local Research Ethics Committee (Queen
Elizabeth Hospital, Birmingham, UK) and the University
Hospital Birmingham Trust (Queen Elizabeth Hospital).
All liver tissue was collected with informed consent. Liver
tissue from nondiseased liver was used for immunohisto-
chemical studies. Nondiseased liver was obtained either
from patients undergoing hemi-hepatectomy to remove
liver metastases or from organ donors in whom the liver
tissue was not used for transplantation.
Isolation and Culture of Human HSECs
Liver endothelial cells were isolated from human liver
tissue (surplus to surgical requirements) as previously
described using a modified collagenase digestion tech-
nique.32 Briefly, nonparenchymal cells were separated
by density gradient centrifugation over metrizamide
(Sigma-Aldrich, St. Louis, MO), and endothelial cells
were isolated from the resultant heterogeneous cell mix-
ture by positive immunomagnetic selection using anti-
bodies against CD31 (M823, 10 g/ml; Dako, Ely, UK)
and Dynabeads conjugated with goat-anti-mouse mono-
clonal antibody (Dynal Biotech, Wirral, UK) according to
the manufacturer’s protocol.
Maintenance and Culture of HSECs
Following isolation, HSECs were cultured in complete
medium composed of human endothelial basal growth
medium (Invitrogen, Carlsbad, CA), 10% AB human se-
rum (HD Supplies, Glasgow, UK), and 10 ng/ml vascular
endothelial growth factor and 10 ng/ml hepatocyte
growth factor (R&D Systems, Minneapolis, MN). The cells
were propagated in collagen-coated culture flasks and
maintained at 37°C in a humidified 5% CO2 incubator
until cells were confluent.
Immunohistochemistry and Dual-Color
Co-Immunofluorescence
The following primary antibodies were used: DC-SIGN
(MAB161, IgG2b) and DC-SIGNR (MAB162, IgG2b) from
R&D Systems, LYVE-1 (8C, IgG1; a gift from David
Jackson, University of Oxford), CD68 (EBM11, IgG1;
from Abcam, Cambridge, UK), and mannose receptor
(MCA2155, IgG1; from Serotec Ltd., Oxford, UK). 5-m
cryostat sections derived from normal liver were fixed in
acetone for 10 minutes and stained using a standard
alkaline phosphatase anti-alkaline phosphatase tech-
nique. Briefly, primary antibody was followed by rabbit
anti-mouse monoclonal and mouse monoclonal alkaline
phosphatase anti-alkaline phosphatase (Dako). The stain
was developed with fast red and naphthol AS-MX phos-
phate substrate (Sigma-Aldrich). Sections for dual immu-
nofluorescence were prewetted with staining buffer
(phosphate-buffered saline containing 10% fetal calf se-
rum and 0.1% sodium azide) for 10 minutes. Slides were
incubated with primary antibodies diluted in staining
buffer for 1 hour in a humidified chamber. Control sec-
tions were incubated with isotype-matched IgG2b or
IgG1 (R&D Systems). Sections were stained with goat
anti-mouse IgG2b Alexa Fluor (Molecular Probes, Eu-
gene, OR) and goat anti-mouse IgG1 fluorescein isothio-
cyanate (Serotec). Immunofluorescence was assessed
using AxioVision software (Carl Zeiss MicroImaging, Inc.,
Jena, Germany).
DC-SIGN and DC-SIGNR Bind Glycoprotein 201
AJP July 2006, Vol. 169, No. 1
Measurement of Cell-Surface Molecules on
HSECs
HSECs were plated at 1  105 ml1 and grown to con-
fluence in collagen-coated 96-well flat bottom plates (BD
Falcon, Oxford, UK). Cells were left under basal condi-
tions or stimulated with cytokines for 24 hours (10 ng/ml
recombinant tumor necrosis factor- (TNF-), IL-17, IL-
10, or 100 ng/ml recombinant IL-4, all from PeproTech,
London, UK). Following stimulation the cell monolayers
were fixed in methanol. Nonspecific binding of monoclo-
nal antibody (mAb) was inhibited by preincubation of
cells for 1 hour at 37°C with 4% goat serum (Sigma)
before the addition of mouse-anti-human mAbs (DC-
SIGN: MAB161; DC-SIGNR: MAB162 (5 g/ml; R&D Sys-
tems); E-Selectin: M7105, 1.6 g/ml; CD31: M0823, 2.25
g/ml (Dako). The cells were then washed thoroughly
before incubation with peroxidase-conjugated goat-anti-
mouse secondary Ab (P0447 1/5000; Dako). An enzyme-
linked immunosorbent assay was developed using O-
phenylenediamine substrate (S2045; Dako) according to
the manufacturer’s instructions, and the enzymatic reac-
tion was stopped by using 0.5 mol/L H2SO4 (Fisher Sci-
entific, Leicestershire, UK). Colorimetric analysis was
performed by measuring absorbance values at 490 nm
using an MRX plate reader (Dynatech Laboratories, Sus-
sex, UK). All treatments were performed in triplicate for
each experiment.
Soluble HCV E2 Binding and Blocking Assay
293-T cells were transiently transfected with plasmids
expressing HC-J4 E2661 or vector alone (control mock
antigen) with Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. Tissue culture super-
natants containing HC-J4 E2661 were harvested 48
hours after transfection, and the amount of HC-J4 E2
antigen was quantified by enzyme immunoassay, as de-
scribed previously.33
Normal liver sections were preincubated with isotype-
matched IgG2b (control block), DC-SIGN, DC-SIGNR (5
g/ml; both from R&D Systems), or mannan (20 g/ml;
Sigma-Aldrich) for 1 hour, washed and then incubated
with mock antigen or HC-J4 E2661 at a saturating con-
centration in phosphate-buffered saline/1% fetal bovine
serum/0.05% sodium azide/1 mmol/L CaCl2 for 1 hour at
room temperature, washed, and labeled with rat anti-E2
mAb 9/75, which recognizes the CD81-binding site on E2
and hence fails to interact with E2-CD81 complexes.33
Detection of binding on normal liver section was as de-
scribed above using immunofluorescence with goat anti-
rat fluorescein isothiocyanate (Serotec). Immunofluores-
cence was assessed using AxioVision software (Carl
Zeiss MicroImaging, Inc.).
Flow Cytometry
HSECs were dissociated from the flask using trypsin
(Invitrogen), washed, and preincubated in human immu-
noglobulins to block Fc receptors. The HCV E2 binding
and blocking assay was as described above. The
cells were fixed in paraformaldehyde (Sigma-Aldrich),
washed, and resuspended in phosphate-buffered saline/
10% fetal calf serum before analysis on an Epics XL flow
cytometer (Beckman Coulter, Fullerton, CA) using Sum-
mit software (DakoCytomation, Glostrup, Denmark).
HCV Pseudoparticle Generation and Infection
HCV pseudoparticles (HCVpp) were generated as previ-
ously described.21 Briefly, 293-T cells were cotrans-
fected with pNL4–3.Luc.R-.E- and a plasmid expressing
strain H and HCJ4 E1E2 and vesicular stomatitis virus G
protein using Lipofectamine 2000 (Invitrogen). Medium
was replaced with Dulbecco’s modified Eagle’s medi-
um/3% fetal bovine serum after 6 hours. Pseudoparticle-
containing supernatants were collected after 48 hours
and clarified by low speed centrifugation for 10 minutes.
For infection experiments target cells were plated into
96-well plates at 1.2  104 per well 24 hours before
infection. Pseudoparticle-containing supernatants were
diluted in Dulbecco’s modified Eagle’s medium/3% fetal
bovine serum with 4 g/ml Polybrene with or without the
desired lipoprotein species. The mixture was incubated
at 37°C for 1 hour before being applied to the target cells
for 4 to 6 hours. Pseudoparticles were removed, and the
cells were incubated for a further 72 hours. Cells were
lysed with 40 l of Cell Culture Lysis Reagent (Promega,
Madison, WI), and infection was measured by quantifying
the luciferase reporter gene by the addition of 50 l of
luciferase substrate (Promega) using a Centro LB960
luminometer (Berthold Technologies, Bad Wildbad,
Germany).
Generation of J6/JFH Virus Stocks and
Culturing of Infected Huh-7.5 Cells with
Human HSECs
Huh 7.5 cells were trypsinized, harvested by centrifuga-
tion (500  g, 5 minutes), washed twice, and resus-
pended in ice-cold phosphate-buffered saline at 1.5 
107 cells/ml. One microgram of FL-J6/JFH RNA was
mixed with 0.4 ml of cells in a 0.2-cm gap cuvette and
pulsed using a BTX ElectroSquarePorator (Harvard Ap-
paratus, Hollistion, MA) as described previously.26 Elec-
Figure 1. HSECs express both DC-SIGN and DC-SIGNR. Immunofluores-
cence was used to demonstrate the presence of DC-SIGN on HSEC. A:
Primary cultures of HSEC-expressed DC-SIGN. B: Cells from the same prep-
aration were also DC-SIGNR-positive.
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troporated cells were allowed to recover for 10 minutes at
room temperature before the addition of complete media
and plated into a 150-mm diameter cell culture dish. After
72 hours, virus containing supernatant was harvested
and viral stocks stored at 80°C.
Naı¨ve Huh-7.5 cells were infected with J6/JFH at a
multiplicity of infection of 0.01, and the cells were main-
tained in culture for 3 days. The frequency of HCV-in-
fected cells in the culture was investigated by staining
cells for the expression of NS5A as previously de-
scribed.26 The persistently infected Huh-7.5 culture was
mixed 1:4 with primary HSECs, cultured for 48 hours, and
stained for HCV NS5A expression.26
Results
Expression and Cytokine Regulation of DC-
SIGN and DC-SIGNR on HSECs
HSECs were isolated from human liver tissue, propa-
gated in cell culture, and shown to internalize acetylated
low density lipoprotein as previously described.32 Mono-
clonal antibodies specific for DC-SIGN and DC-SIGNR
bound the cultured cells (Figure 1, A and B). Appropriate
isotype-matched controls were negative in staining (not
shown). DC-SIGN expression during monocyte differen-
tiation is dependent on the cytokine microenviron-
ment.34,35 To determine whether cytokines similarly reg-
ulate DC-SIGN and DC-SIGNR expression in HSECs, the
cells were treated with various cytokines for 24 hours,
and lectin expression was measured in a quantitative
cell-based immunoassay. IL-4 significantly increased ex-
pression of DC-SIGN (P  0.02) and DC-SIGNR (P 
0.05), TNF- and IL-17 had a small but nonsignificant
effect (Figure 2), whereas, IFN- and IL-12 had no de-
tectable effect (data not shown). CD31, an endothelial
Figure 2. Treatment with IL-4 increases the expression of DC-SIGNR and
DC-SIGN on primary HSEC. HSECs were stimulated with IL-4 (100 ng ml1),
TNF- (10 ng ml1), or IL-17 (10 ng ml1) for 24 hours before assessing
expression of DC-SIGNR (LS), DC-SIGN (DCS), CD31, and E-Selectin
(CD62E) by enzyme-linked immunosorbent assay. An equivalent volume of
complete media was added to the control wells. Data represent mean  SE
of four experiments using different HSEC isolates. IL-4 induced a significant
increase in DC-SIGNR and DC-SIGN expression (P  0.05 and P  0.02;
using Student’s t-test). * P  0.05; ** P  0.02.
Figure 3. DC-SIGNR and DC-SIGN on HSECs can bind HCV E2. Binding
assays were performed using a strain of HCV HCJ4 with minimal interaction
with CD81 when expressed as a truncated E2 species and flow cytometric
detection with an antibody raised against E2, which fails to detect E2-CD81
complexes. A: Flow cytometric analysis of HCV E2 binding following treat-
ment with IL-4 (100 ng ml1 for 24 hours) confirmed that IL-4 significantly
increased the expression of both C-type lectins, which led to an increased
HCV E2 interaction with the stimulated HSECs (red) compared to unstimu-
lated HSECs (green) and control mock protein in black. B: HCV E2 bound
to HSECs (red), and this interaction was inhibited by prior incubation of the
cells with mAbs specific for DC-SIGN (gray) and DC-SIGNR (green line)
alone or in combination (blue). Control binding with mock protein is in
black.
Figure 4. Distribution of DC-SIGNR and DC-SIGN expression in liver tissue.
The left panel is a representative immunofluorescent staining (original
magnification, 10) showing DC-SIGNR is not expressed on portal tracts
(PT) as shown with alkaline phosphatase anti-alkaline phosphatase staining
on the right panel (original magnification, 20). DC-SIGN, however, does
not have a patchy distribution and is expressed around portal tracts. CV,
central vein.
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marker, and E-Selectin were included as positive
controls.
Expression of Functionally Active DC-SIGN and
DC-SIGNR on HSECs
To determine whether these lectins are able to interact
with high mannose-containing glycoproteins we tested
their ability to bind a truncated version of HCV E2,
previously reported to interact with DC-SIGN and DC-
SIGNR.6 Since HCV E2 interacts with the viral co-
receptor CD81,20 –22,36 which is also expressed on
HSECs (data not shown), we selected a strain of HCV
HCJ4 that shows minimal interaction with CD81 when
expressed as a truncated E2 species and detected
cell-bound E2 with a mAb that fails to detect E2 when
complexed with CD81.22,33 The IL-4-stimulated ex-
pression of DC-SIGN and DC-SIGNR induced a con-
comitant increase in HCV E2 binding, further support-
ing the cytokine regulation of these functionally active
C-type lectins on HSECs (Figure 3A). HCV E2 binding
to IL-4-stimulated HSECs could be inhibited by prior
incubation of the cells with mAbs specific for either
DC-SIGN or DC-SIGNR. Preincubation with combina-
tions of both DC-SIGN and DC-SIGNR mAbs did not
alter the inhibition of HCV E2 binding seen with the
single mAb alone (Figure 3B). The finding of complete
block with each antibody is surprising. One possible
interpretation derives from the observation that these
lectins exist as tetramers at the cell surface.37,38 Our
finding that primary HSECs express both receptors
may support a model for hetero-oligomer formation
between the two related lectins, which may explain our
observations with antibody blocking HCV E2 to these
primary cell types. We have shown previously that the
mAbs used in this study bind specifically to 293-T cells
transduced to express the appropriate receptors.39
DC-SIGN and DC-SIGNR Expression in
Liver Tissue
To evaluate the distribution of these lectins in normal
human liver we examined the ability of DC-SIGN- and
DC-SIGNR-specific mAbs to react with cells within tissue
sections by immunohistochemistry. The staining pattern
of the two receptors differed: DC-SIGNR was only ex-
pressed within the liver sinusoids, whereas DC-SIGN was
detected on portal tracts in addition to the hepatic sinu-
soidal endothelium (Figure 4). DC-SIGN and DC-SIGNR
expression by endothelial cells in the sinusoids was con-
firmed by dual staining with anti-LYVE-1 antibody, which
selectively stains sinusoidal endothelial cells in human
liver (Figure 5).40 DC-SIGN expression on Kupffer cells
was demonstrated by dual staining with the macrophage
mannose receptor-positive cells and CD68 (Figure 6).
There appear to be differences in the intensity of DC-
SIGN-R staining across the sinusoidal bed with a rela-
tively weaker staining in the periportal sinusoids. This
may reflect differences in the local microenvironment, a
conclusion that is supported by the observations that
other proteins, including adhesion molecules, are differ-
entially expressed across hepatic sinusoids. Appropriate
isotype-matched controls were negative in staining (data
not shown).
To assess whether DC-SIGN and DC-SIGNR ex-
pressed in normal liver are able to interact with HCV E2,
intact liver sections were incubated with truncated E2
from HC-J4 E2661 and bound antigen visualized with rat
anti-E2 antibody 9/75, which recognizes the CD81-bind-
ing site on E2 and hence fails to interact with E2-CD81
complexes. E2 bound diffusely and in focal areas within
the sinusoids, and binding could be inhibited by mannan,
a sugar molecule reported to interact with the carbohy-
drate recognition sites of C-type lectins (Figure 7, A and
B). To confirm the identity of cells that bound HCV E2,
sections were counterstained with mAbs specific for
macrophage mannose receptor, CD68, and DC-SIGNR
(Figure 8, A and B). These data confirm that HCV E2
interacts with both Kupffer and sinusoidal endothelial
Figure 5. DC-SIGN and DC-SIGNR colocalize with LYVE-1 staining on sinu-
soidal endothelium. Because LYVE-1 expression in the liver is restricted to
sinusoidal endothelium, we used LYVE-1 staining to confirm the cellular
localization of DC-SIGN staining. DC-SIGNR and DC-SIGN are stained red
and LYVE-1 green. Colocalization is demonstrated in merged images by
yellow staining confirming that DC-SIGN and DC-SIGNR are expressed on
sinusoidal endothelial cells (original magnification, 20).
Figure 6. DC-SIGN is detected on Kupffer cells in liver tissue. Immunoflu-
orescent staining of mannose receptor and CD68 (green) was used to detect
Kupffer cells, and DC-SIGN stained red. Colocalization of the two receptors
is seen as yellow staining confirming that Kupffer cells express DC-SIGN in
the liver (original magnification, 40).
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cells within the liver, consistent with the pattern of DC-
SIGN and DC-SIGNR expression. To confirm that HCV E2
binding was dependent on DC-SIGN and DC-SIGNR ex-
pression, liver sections were preincubated with mAbs
specific for DC-SIGN and DC-SIGNR and evaluated for
their ability to bind HCV E2. Pretreatment of liver sections
with a control isotype-matched IgG2b mouse immuno-
globulin had no effect on E2 binding (Figure 9A). The
mAb specific for DC-SIGN inhibited E2 binding to both
Kupffer and sinusoidal cells (Figure 9B), whereas the
mAb specific for DC-SIGNR only attenuated E2 binding
to sinusoidal cells (Figure 9C). However, we also used E2
derived from HCV strain H77, which binds with high
affinity to CD81. To distinguish E2-H77 interacting with
CD81 and the lectins DC-SIGN(R), we used two anti-E2
mAbs that could discriminate between E2 bound to
CD81. These experiments allowed us to confirm the re-
sults we obtained with E2-HCJ4 with an independent
strain of E2 (data not shown). These data conclusively
show DC-SIGN and DC-SIGNR expressed in normal liver
are able to interact with HCV E2.
HSECs Do Not Support HCV Infection
As a model for studying HCV interaction with DC-SIGN/
DC-SIGNR in the liver, several investigators have ex-
pressed DC-SIGN and DC-SIGNR in heterologous cell
systems and studied HCVpp interactions.4–6,35 HCVpp
fails to infect cells engineered to express DC-SIGN and
DC-SIGNR; however, infectivity can be transferred to per-
missive hepatoma cells,41,42 suggesting that these lectin
molecules may act as ‘transfer receptors’ within the liver,
enabling endothelial cells to ‘trap and concentrate’ HCV
within the sinusoids and to transfer virus to the permissive
underlying hepatocytes. However, the assumption that
DC-SIGN/DC-SIGNR expressed in heterologous cells ac-
curately mimics primary HSEC lectin-dependent interac-
tions with HCV is undermined by a recent report43 that
DC-SIGN interaction with human immunodeficiency virus
is dependent on the cellular context. To address this
issue we purified HSECs from three donor livers, con-
firmed CD81, DC-SIGN, and DC-SIGNR expression, and
evaluated their ability to support HCVpp entry. Virus entry
and uncoating is quantified by luciferase expression in
the target cell under the control of the retroviral promoter
and is directly proportional to the frequency of infected
cells.21 Pseudotypic particles with no envelope glyco-
proteins were used to control for nonspecific particle
uptake and viruses expressing vesicular stomatitis virus
G served as a control for retroviral RNA transcription and
translation of the luciferase reporter gene within the pri-
mary cells. HCVpp bearing strain HCJ4 and H77 glyco-
proteins infected Hep3B hepatoma cells and primary
human hepatocytes but failed to infect HSECs (Figure
10). Vesicular stomatitis virus pseudoparticle infected all
Figure 7. HCV E2 glycoprotein binding to sinusoids in normal liver tissue
can be blocked by mannan. A: HCV E2 glycoprotein binding on normal liver
tissue is seen on sinusoids and plump cells with Kupffer cell morphology. B:
The HCV E2 binding can be inhibited by preincubating with mannan (20
g/ml) for 1 hour before the addition of HCV E2 glycoprotein resulting in the
attenuation of both the sinusoidal and Kupffer cell staining. Original magni-
fication, 20.
Figure 8. HCV E2 binds to Kupffer cells and sinusoidal endothelial cells in
liver tissue. A: Kupffer cells labeled with macrophage mannose receptor
(original magnification40, lower panel) and CD68 (original magnification
20, upper panel) in red are seen clearly in the sinusoidal space, and HCV
E2 (green) is shown binding to these cells. Colocalization of macrophage
mannose receptor and CD68 with HCV E2 is demonstrated by the yellow
staining in merged images. B: HCV E2 (green) also binds to DC-SIGNR-
expressing sinusoidal endothelium (red) as confirmed by colocalization
(yellow). Original magnification, 20.
Figure 9. HCV E2 binds to normal sinusoidal endothelium and Kupffer cells
via DC-SIGNR and DC-SIGN. A: Normal liver sections were preincubated
with an isotype IgG2b control antibody an hour before labeling with HCV E2
glycoprotein (green). The staining pattern reveals sinusoidal and Kupffer cell
distribution. B: When preincubated with DC-SIGN mAb (5 g/ml) the bind-
ing of HCV E2 to sinusoidal and Kupffer cells was attenuated. C: Preincuba-
tion with DC-SIGNR (5 g ml1) only attenuated binding to sinusoidal
endothelium. Original magnification, 20.
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target cells with different efficiencies, and particles with
no envelope glycoproteins gave background signals
comparable to uninfected cells. Treatment of HSECs with
IL-4 24 hours before infection did not alter the results. To
establish whether J6/JFH HCVcc could infect HSECs, we
cocultured J6/JFH-infected Huh-7.5 cells with primary
HSECs. After 48 hours, HCV infection in the isolated and
cocultured cells was determined by immunostaining for
HCV NS5A antigen. Viral antigen was only detected in the
Huh-7.5 cells (Figure 11), consistent with the HSECs cells
failing to support HCVpp infection. These data confirm
that sinusoidal endothelial cells are not permissive for
HCV infection.
Discussion
Our findings demonstrate that human HSECs express
DC-SIGNR and DC-SIGN in vivo and that both receptors
can interact with HCV E2. Expression of DC-SIGN by
HSECs provides further evidence for the ability of HSECs
to process and present microbial antigens. We show that
primary HSECs are unable to support HCVpp and HCVcc
entry. These data are consistent with a model where
DC-SIGN and DC-SIGNR on sinusoidal endothelium pro-
vide a mechanism for high affinity binding of circulating
HCV within the liver sinusoids allowing transfer of the
virus to underlying hepatocytes, in a manner analogous
to dendritic cell DC-SIGN presenting HIV to T lympho-
cytes.41 Viral capture at the cell surface can be rate
limiting for infection,11,44,45 suggesting that expression of
both DC-SIGN and DC-SIGNR on HSECs may enhance
the rate and efficiency of virus infection of hepatocytes
expressing the coreceptors, CD81 and scavenger recep-
tor BI.11,46
DC-SIGN is able to recognize highly mannosylated
glycoproteins at the surface of a broad range of patho-
gens, including viruses, bacteria, fungi, and para-
sites.47,48 For at least some of these agents, this interac-
tion appears to be an important component of the
infection process, as demonstrated for human immuno-
deficiency virus and Ebola virus, making DC-SIGN an
attractive target for drug design.47,49,50 Glycodendritic
polymers that block the binding of pathogen glycopro-
teins to DC-SIGN inhibit DC-SIGN-mediated infection in
an Ebola-pseudotyped viral model.47,49 In addition, these
lectins may provide a viral escape mechanism as uptake
of HCV by DC-SIGN and DC-SIGNR has been reported to
target nonlysosomal compartments in immature DCs,
whereas Lewis X antigen, another ligand of DC-SIGN,
was internalized to lysosomes.51 Thus, DC-SIGN and
DC-SIGNR on HSECs may not only act to capture HCV
from blood but may also allow HSECs to act as reservoirs
for HCV, allowing the virus to avoid detection and to be
transmitted to the underlying hepatocyte, the primary
target for HCV.
The detection of functional DC-SIGN on HSECs is fur-
ther evidence of the unique antigen-capturing and -scav-
enging properties of these cells. HSECs can act as or-
gan-resident, nonmyeloid antigen processing cells by
cross-presenting soluble exogenous antigen to CD8 T
cells using similar mechanisms of antigen processing
and presentation as dendritic cells. However, the out-
come of cross-presentation by HSECs is CD8 T cell
tolerance, and major histocompatibility class II-restricted
antigen presentation by HSECs to naive CD4 T cells
leads to differentiation into IL-4/IL-10-expressing Th2
cells.30,52 The presence of DC-SIGN on HSECs may al-
low these cells to capture and endocytose a range of
microbial pathogens for subsequent presentation to the
immune system. Furthermore, DC-SIGN can also act as
an adhesion receptor to support interactions with inter-
cellular adhesion molecule-3 on T cells during antigen
presentation and on dendritic cells during transendothe-
lial migration, extending the potential role of HSECs in
immune responses.
Figure 10. Sinusoidal endothelium does not support HCVpp viral infection.
Because HSECs can support binding of HCV glycoproteins, we went on to
determine whether they can also support viral infection. HSECs were pre-
pared from three different livers, and all infections were preformed in
triplicates. HCVpp bearing strain HCJ4 and H77 glycoproteins infected
Hep3B hepatoma cells but failed to infect HSECs. Preincubating the HSECs
with IL-4 (100 ng/ml) for 24 hours did not alter the results. HCV-MLV and
HCV-No env served as positive and negative control experiments, respec-
tively. Successful infection was measured by quantifying the luciferase re-
porter gene and expressed as relative light units (RLU).
Figure 11. Infection of Huh-7.5 cells, but not primary HSECs, with J6/JFH
HCVcc in coculture. Huh-7.5 cells (A) and primary HSECs (B) have contrast-
ing and distinctive morphologies in culture. To assess whether primary
HSECs can be infected with J6/JFH, HSECs were cultured with persistently
infected Huh-7.5 cells. The cells were mixed at an Huh-7.5:HSEC ratio of 1:4
and seeded at 200,000 cells per well in collagen coated 6-well plates. The
following day the coculture had a distinct appearance in which HSECs and
Huh-7.5 cells formed discrete foci (C). A control population of J6/JFH-
infected Huh-7.5 cells was seeded at the same density in the absence of
HSECs (D). Cocultures were maintained for 48 hours, and J6/JFH infection
was monitored by staining for HCV NS5A antigen. Viral antigen was detected
in the persistently infected Huh-7.5 cells (D) and within the coculture (E).
Viral antigen was only detected in the Huh-7.5 cells and not within the
HSECs, consistent with primary HSECs failing to support HCVpp infection
(Figure 10).
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We found that IL-4 but not IL-12, interferon-, TNF-, or
IL-17 increased expression of DC-SIGN on HSECs in
vitro. IL-4 has been shown to increase expression of
DC-SIGN on monocytes and THP-1 cells.34,35 In mono-
cytes IL-4 treatment favors differentiation into dendritic
cells rather than macrophages,53,54 and evidence sug-
gests that IL-4 is the key cytokine for DC-SIGN acquisi-
tion during monocyte-derived dendritic cell differentia-
tion. Our findings provide evidence that DC-SIGN
expression is IL-4-dependent in endothelial cells as well
as myeloid cells, although we did not see suppression of
DC-SIGN by TNF- treatment as reported with macro-
phages.34,35 The lack of response to IL-12 and interfer-
on- suggests that induction of DC-SIGN on HSECs will
be promoted by Th2 rather than Th1 cytokine responses
consistent with the requirement for vigorous Th1 re-
sponses to clear viral infection.
In conclusion, this report is the first description of
DC-SIGN expression on sinusoidal endothelium and pro-
vides evidence of the unique antigen-processing and
-scavenging properties of these cells. The distinct distri-
bution of DC-SIGN and DC-SIGNR in the liver and the
ability of both lectins to bind HCV E2 in vivo suggest a
complementary role in trapping HCV within the hepatic
sinusoids. The up-regulation of DC-SIGN and DC-SIGNR
by IL-4 suggests that the local cytokine microenviron-
ment may affect HCV cell attachment and infectivity.
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